Literature DB >> 32441411

Questionnaire-based epidemiological study of hidradenitis suppurativa in Japan revealing characteristics different from those in Western countries.

Koremasa Hayama1, Hideki Fujita1, Takashi Hashimoto2, Tadashi Terui1.   

Abstract

Hidradenitis suppurativa (HS) is a chronic relapsing skin disease localized mainly on the apocrine gland-bearing areas. In Japan, HS is yet to be fully understood, and no criteria have been established for its diagnosis or severity assessment. The purpose of this study was to investigate and characterize HS in Japan. We conducted a nationwide questionnaire-based study, in which Japanese diagnostic criteria were proposed. Question items included age, sex, disease duration, past history, family history, smoking status, disease severity scores (Hurley stage, modified Sartorius score and Physician Global Assessment [PGA] score), treatments, comorbidities and prognosis. We analyzed 300 patients (219 males and 81 females) diagnosed with HS based on our criteria. Average disease duration was 92.3 ± 6.82 months. Only 12 (4%) patients had a family history of HS. Disease severity was classified by PGA score (mild, 100 [33.3%]; moderate, 133 [44.3%]; severe, 34 [11.3%]; most severe, 29 [9.7%]) and Hurley stage (I, 69 [23%]; II, 109 [36.3%]; III, 121 [40.3%]). Disease severities based on PGA score and Hurley stage were positively correlated to modified Sartorius score using the Kruskal-Wallis test (P < 0.001, respectively). Patients with diabetes mellitus showed higher PGA scores (χ2  = 10.977, P = 0.01185). Presence of axillary lesions related to higher PGA scores (χ2  = 8.6378, P = 0.03452). The results in this study and previous studies indicate that Japanese HS patients have different backgrounds from those in Western countries, and are characterized by male predominance, higher incidence of Hurley stages II and III, higher PGA scores in patients with axillary lesions and much fewer familial cases.
© 2020 Japanese Dermatological Association.

Entities:  

Keywords:  Hurley stage; epidemiology; hidradenitis suppurativa; modified Sartorius score; physician’s global assessment

Mesh:

Year:  2020        PMID: 32441411      PMCID: PMC7818453          DOI: 10.1111/1346-8138.15378

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  17 in total

1.  Questionnaire surveillance of hidradenitis suppurativa in Japan.

Authors:  Ichiro Kurokawa; Nobukazu Hayashi
Journal:  J Dermatol       Date:  2015-04-20       Impact factor: 4.005

2.  Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota.

Authors:  Benjamin G Vazquez; Ali Alikhan; Amy L Weaver; David A Wetter; Mark D Davis
Journal:  J Invest Dermatol       Date:  2012-08-30       Impact factor: 8.551

3.  Demographic and Clinical Features of Hidradenitis Suppurativa in Turkey.

Authors:  Mavişe Yüksel; Pelin Basım
Journal:  J Cutan Med Surg       Date:  2019-11-07       Impact factor: 2.092

Review 4.  γ-Secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis.

Authors:  Andrew E Pink; Michael A Simpson; Nemesha Desai; Richard C Trembath; Jonathan N W Barker
Journal:  J Invest Dermatol       Date:  2012-10-25       Impact factor: 8.551

5.  European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa.

Authors:  C C Zouboulis; N Desai; L Emtestam; R E Hunger; D Ioannides; I Juhász; J Lapins; L Matusiak; E P Prens; J Revuz; S Schneider-Burrus; J C Szepietowski; H H van der Zee; G B E Jemec
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-01-30       Impact factor: 6.166

6.  Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies.

Authors:  Jean E Revuz; Florence Canoui-Poitrine; Pierre Wolkenstein; Cedric Viallette; Germaine Gabison; Florence Pouget; Florence Poli; Ousmane Faye; Jean Claude Roujeau; Genevieve Bonnelye; Jean Jacques Grob; Sylvie Bastuji-Garin
Journal:  J Am Acad Dermatol       Date:  2008-10       Impact factor: 11.527

7.  Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study.

Authors:  J H Lee; H S Kwon; H M Jung; G M Kim; J M Bae
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-05-31       Impact factor: 6.166

8.  A novel splice site mutation in NCSTN underlies a Japanese family with hidradenitis suppurativa.

Authors:  Y Nomura; T Nomura; K Sakai; K Sasaki; Y Ohguchi; O Mizuno; H Hata; S Aoyagi; R Abe; Y Itaya; M Akiyama; H Shimizu
Journal:  Br J Dermatol       Date:  2013-01       Impact factor: 9.302

9.  Demographic and clinical features of hidradenitis suppurativa in Korea.

Authors:  Ji Hoon Yang; Jungyoon Moon; Young Chul Kye; Kwang Joong Kim; Myeung Nam Kim; Young Suck Ro; Mi Youn Park; Hyo Hyun Ahn; Mi Woo Lee; Weon Ju Lee; Ju Hee Lee; Jee Bum Lee; Min Soo Jang; Yu Sung Choi; You Won Choi; Dae Hun Suh
Journal:  J Dermatol       Date:  2018-10-08       Impact factor: 4.005

10.  Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities.

Authors:  J J Crowley; J R Mekkes; C C Zouboulis; N Scheinfeld; A Kimball; M Sundaram; Y Gu; M M Okun; F Kerdel
Journal:  Br J Dermatol       Date:  2014-11-20       Impact factor: 9.302

View more
  5 in total

1.  Overall Impairment of Quality of Life in Japanese Patients with Hidradenitis Suppurativa: Comparison with National Standard.

Authors:  Koremasa Hayama; Hideki Fujita; Takashi Hashimoto; Tadashi Terui
Journal:  Acta Derm Venereol       Date:  2022-01-18       Impact factor: 3.875

2.  Characterization of comorbidity heterogeneity among 13,667 patients with hidradenitis suppurativa.

Authors:  Vivian J Hua; James M Kilgour; Hyunje G Cho; Shufeng Li; Kavita Y Sarin
Journal:  JCI Insight       Date:  2021-11-08

3.  Recent advances in hidradenitis suppurativa: Role of race, genetics, and immunology.

Authors:  Gautham Vellaichamy; Anya T Amin; Peter Dimitrion; Zaakir Hamzavi; Li Zhou; Indra Adrianto; Qing-Sheng Mi
Journal:  Front Genet       Date:  2022-08-26       Impact factor: 4.772

4.  Long-term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: Open-label phase 3 results.

Authors:  Akimichi Morita; Hidetoshi Takahashi; Kentaro Ozawa; Shinichi Imafuku; Nakama Takekuni; Kenzo Takahashi; Takashi Matsuyama; Yukari Okubo; Yiwei Zhao; Susumu Kitamura; Keiko Takei; Masayuki Yokoyama; Nobukazu Hayashi; Tadashi Terui
Journal:  J Dermatol       Date:  2020-10-07       Impact factor: 4.005

5.  Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan.

Authors:  Nobukazu Hayashi; Koremasa Hayama; Kenzo Takahashi; Ichiro Kurokawa; Masateru Okazaki; Tomoko Kashiwagi; Eri Iwashita; Tadashi Terui
Journal:  J Dermatol       Date:  2022-01-17       Impact factor: 3.468

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.